Načítá se...
Advances in the treatment of newly diagnosed glioblastoma
Glioblastoma is a refractory malignancy with limited treatment options at tumor recurrence. Only a small proportion of patients survive 2 years or longer with the current standard of care. Gene expression profiling can segregate newly diagnosed patients into groups with different prognoses, and thes...
Uloženo v:
| Vydáno v: | BMC Med |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4673777/ https://ncbi.nlm.nih.gov/pubmed/26646075 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12916-015-0536-8 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|